Arbutus Biopharma to present 5 abstracts, including late-breaker, highlighting advancements in chronic hepatitis B treatment at EASL 2025
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association… read more.
